Citius Pharmaceuticals Inc (CTXR) Stock Price, Quote & News

Latest News on CTXR

Apr 1, 2025, 9:00 AM EDT - 1 day ago

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Feb 14, 2025, 4:30 PM EST - 6 weeks ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CTOR

Feb 6, 2025, 8:55 AM EST - 7 weeks ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTOR

Jan 8, 2025, 8:00 AM EST - 3 months ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Jan 7, 2025, 8:08 AM EST - 3 months ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTOR

Jan 6, 2025, 7:50 AM EST - 3 months ago

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

CTOR

Dec 27, 2024, 5:00 PM EST - 3 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Nov 25, 2024, 8:03 AM EST - 4 months ago

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Nov 22, 2024, 9:00 AM EST - 4 months ago

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Nov 18, 2024, 4:05 PM EST - 4 months ago

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

Nov 15, 2024, 1:30 PM EST - 4 months ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

Nov 11, 2024, 8:45 AM EST - 5 months ago

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

Sep 5, 2024, 4:30 PM EDT - 7 months ago

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:30 AM EDT - 7 months ago

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

Aug 12, 2024, 5:28 PM EDT - 8 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:22 PM EDT - 8 months ago

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.

Aug 12, 2024, 8:00 AM EDT - 8 months ago

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

$Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma$

Aug 8, 2024, 6:59 AM EDT - 8 months ago

Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Aug 5, 2024, 8:00 AM EDT - 8 months ago

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

Jul 18, 2024, 7:00 AM EDT - 9 months ago

Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)

Jul 17, 2024, 8:00 AM EDT - 9 months ago

Analysts Hunt for Undervalued Biotech Stocks

Jul 11, 2024, 11:00 AM EDT - 9 months ago

Bloodstream Infections - From Threats to Solutions

Jul 11, 2024, 8:00 AM EDT - 9 months ago

Biopharma Stocks Transformative Innovation for the Future of Health

Jul 10, 2024, 9:10 AM EDT - 9 months ago

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates

May 29, 2024, 8:30 AM EDT - 11 months ago

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

May 21, 2024, 7:00 AM EDT - 11 months ago

Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

May 14, 2024, 4:05 PM EDT - 11 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update

May 10, 2024, 8:30 AM EDT - 11 months ago

Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences

Apr 30, 2024, 4:05 PM EDT - 1 year ago

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

Apr 26, 2024, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

Apr 11, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Apr 4, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

$Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma$

Mar 18, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Mar 7, 2024, 8:30 AM EST - 1 year ago

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program

Feb 26, 2024, 7:30 AM EST - 1 year ago

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

Feb 23, 2024, 8:30 AM EST - 1 year ago

Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences

Feb 14, 2024, 4:30 PM EST - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

$Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma$